ClinicalTrials.gg
RecruitingNCT06582121SOMPARKUpdated Mar 6, 2026

Study of Sleep Disorders in Prodromal and Definite Parkinsons Disease

An interventional study of Polysomnography in Parkinson Disease and REM Sleep Behavior Disorder (iRBD), sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 6 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
457
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Parkinson Disease by Assistance Publique - Hôpitaux de Paris — 3 open to participants now, 3 under way, none of them phase 3. Parkinson Disease · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
2nd of 15
457 · median 60
Started
2025
the only one that year
No phase
10 of 21
3 open now
Registered
18th of 21
by date

Among the 21 studies in Parkinson Disease by Assistance Publique - Hôpitaux de Paris, this one is the 2nd largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2025, is one of 10 with no phase, and was the 18th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

3 of the 21 studies in Parkinson Disease by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Parkinson Disease by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Multicenter controlled study of sleep disorders in isolated REM Behavior Disorder and Parkinson\'s disease (SOMPARK)

Read the detailed description

Sleep disturbances are common and understudied in established or prodromal Parkinson\'s disease. The purpose of this study is to systematically and comprehensively determine the clinical characteristics and electrophysiologic patterns of the major sleep disorders in PD and isolated RBD.

03

Conditions studied

  • Parkinson Disease
  • REM Sleep Behavior Disorder (iRBD)

Keywords

  • Parkinson disease
  • isolated RBD
  • Sleep
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Common to all groups:

  • Age superior 18 years
  • Patients who have received complete information about the study from an investigator and who fully consent to participate.

For Parkinson Disease (PD):

  • Patients followed for PD diagnosed according to international criteria for the diagnosis of PD (MDS criteria),
  • A score greater than 20/30
  • No treatment with deep brain stimulation.

For REM Sleep Behavior Disorder (RBD):

  • Diagnosis of RBD according to ICSD-3 criteria: presence on polysomnography of an abnormal elevation of muscle tone during REM sleep (more than 18% of REM sleep without chin atonia) and/or the presence of REM sleep behaviors on video-polysomnography,
  • Absence of progressive neurodegenerative pathology: absence of diagnostic criteria for PD, multiple system atrophy, or Lewy body dementia.

For healthy controls:

- No neurological or psychiatric disease

Exclusion criteria

Exclusion Criteria:

Common to all groups:

  • Pregnant or breastfeeding women
  • Subjects under guardianship/conservatorship
  • Persons deprived of liberty.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
457 participants (estimated)

Study arms

  • Experimental
    Participants

    Study of the sleep with polysomnography during a 2-days stay in hospital. Other exam will be done during the 2 days.

    Other: Polysomnography

Interventions

  • OtherPolysomnography

    An overnight sleep study

    Also known as: Biology (urine, blood, faeces), Questionnaries, electromyogram, electroencephalogram

06

What researchers measure

Primary outcomes

  1. Polysomnography to compare sleep efficiency

    Using polysomnography to compare sleep efficiency in the 3 study populations during the first night

    Time frame: 25 months

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Apr 2028, 37 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 37 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2024
First posted
Sep 3, 2024
StartActual
Mar 18, 2025
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2028
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06582121
Responsible party
Sponsor
First posted
Sep 3, 2024
Start date
Mar 18, 2025
Primary completion
Apr 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Mar 6, 2026

Study contacts

Isabelle ARNULF, Prof
Contact
isabelle.arnulf@aphp.fr
+33 (0)1 42 16 77 04

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion